Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Summary

The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: * To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area. * To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks. * To evaluate the pharmacokinetics of SR141716.

Timeline

Start

2007-02

Primary completion

2008-11

Completion

2009-02

Drugs

Indications